Overview

Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Status:
Recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

This is an open-label, non-randomized, multicenter, translational Phase 1/2 dose-escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of RSO-021 after intrapleural (IP) administration in patients with malignant pleural effusion (MPE) (non-mesothelioma) and MPE from mesothelioma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

RS Oncology LLC

Treatments:

Thiostrepton